Literature DB >> 157149

Thiamphenicol and lupus nephritis. The effects of long-term therapy on kidney function and pathology: a pilot study.

L O Simpson, I Aarons, J B Howie.   

Abstract

NZB x OUW F1 hybrid mice were treated with thiamphenicol at 25, 50 and 250 mg/kg/day from the time of their first positive antinuclear antibody test until their death. Untreated mice fed the same diet served as controls with body weight, mortality and renal disease patterns conforming to published reports of the biology of the BW mice. Regular testing of urine and bloodm and detailed postmortem examinations showed (a) that with increasing drug dose levels heavy proteinuria was almost eliminated and blood urea concentrations significantly lowered; (b) that in treated and untreated mice moderate to severe anaemia developed, apparently unrelated to the degree of uraemia; (c) that changes in renal function did not correlate with antinuclear antibody activity, nor did the drop in packed cell volume correlate with fixed or free circulating antierythrocyte autoantibody positivity; (d) that histological analysis of renal changes showed that at the highest dose level glomerular lesions were minimal. Thus the prolonged treatment with thiamphenicol reduced the severity of the spontaneous renal disease and resulted in a significant extension of lifespan.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 157149      PMCID: PMC2041425     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  19 in total

1.  Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis.

Authors:  V E POLLAK; C L PIRANI; R M KARK
Journal:  J Lab Clin Med       Date:  1961-04

2.  Lupus nephritis: a clinical and pathologic study based on renal biopsies.

Authors:  R C MUEHRCKE; R M KARK; C L PIRANI; V E POLLAK
Journal:  Medicine (Baltimore)       Date:  1957-02       Impact factor: 1.889

3.  Normal and pathologic anatomy of the reticular tissue in laboratory mice, with a classification and discussion of neoplasms.

Authors:  T B DUNN
Journal:  J Natl Cancer Inst       Date:  1954-06       Impact factor: 13.506

4.  Cyclophosphamide treatment of renal disease in (NZB x NZW) F1 hybrid mice.

Authors:  P J Russell; J D Hicks
Journal:  Lancet       Date:  1968-03-02       Impact factor: 79.321

5.  Therapeutic studies in NZB-W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination.

Authors:  M C Gelfand; A D Steinberg; R Nagle; J H Knepshield
Journal:  Arthritis Rheum       Date:  1972 May-Jun

6.  Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone.

Authors:  M C Gelfand; A D Steinberg
Journal:  Arthritis Rheum       Date:  1972 May-Jun

7.  The development of lymphomas in mice with autoimmune disorders treated with azathioprine.

Authors:  T P Casey
Journal:  Blood       Date:  1968-03       Impact factor: 22.113

8.  Prostaglandin E treatment of NZB/NZW mice.

Authors:  R B Zurier; D M Sayadoff; A B Torrey; N F Rothfield
Journal:  Arthritis Rheum       Date:  1977-03

9.  NZB/NZW mice as a model of systemic lupus erythematosus.

Authors:  E L Dubois; R E Horowitz; H B Demopoulos; R Teplitz
Journal:  JAMA       Date:  1966-01-24       Impact factor: 56.272

10.  Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis.

Authors:  R B Zurier; I Damjanov; D M Sayadoff; N F Rothfield
Journal:  Arthritis Rheum       Date:  1977 Nov-Dec
View more
  1 in total

1.  Late treatment of murine lupus erythematosus with dactinomycin. II. C1 and antibody to DNA.

Authors:  C T Olsen; P O Teague; A E Gabrielsen
Journal:  Immunology       Date:  1981-06       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.